RADX Stock Summary and Trading Ideas (Radiopharm Theranostics Limited - American Depositary Shares | NASDAQ:RADX)

Radiopharm Theranostics Ltd is an Australian-based clinical-stage radiotherapeutics company targeting cancer. The company has a pipeline of approximately four licensed platform technologies, with diagnostic and therapeutic applications at both the pre-clinical and clinical stages of development. The company is engaged in research, development, and commercialization of health technologies.

Radiopharm Theranostics Limited - American Depositary Shares trades on the NASDAQ stock market under the symbol RADX.

As of January 15, 2026, RADX stock price declined to $5.15 with 46,105 million shares trading.

RADX has a beta of -0.05, meaning it tends to be less sensitive to market movements. RADX has a correlation of 0.00 to the broad based SPY ETF.

RADX has a market cap of $40.07 million. This is considered a Sub-Micro Cap stock.

RADX has underperformed the market in the last year with a price return of -4.6% while the SPY ETF gained +20.2%. RADX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -27.6% and -1.3%, respectively, while the SPY returned +4.8% and +1.5%, respectively.

RADX support price is $4.85 and resistance is $5.55 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RADX shares will trade within this expected range on the day.